UA124106C2 - Кристалічні тверді форми інгібітора bet - Google Patents
Кристалічні тверді форми інгібітора bet Download PDFInfo
- Publication number
- UA124106C2 UA124106C2 UAA201900524A UAA201900524A UA124106C2 UA 124106 C2 UA124106 C2 UA 124106C2 UA A201900524 A UAA201900524 A UA A201900524A UA A201900524 A UAA201900524 A UA A201900524A UA 124106 C2 UA124106 C2 UA 124106C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compound
- cancer
- solution
- temperature
- specified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01M—CATCHING, TRAPPING OR SCARING OF ANIMALS; APPARATUS FOR THE DESTRUCTION OF NOXIOUS ANIMALS OR NOXIOUS PLANTS
- A01M31/00—Hunting appliances
- A01M31/06—Decoys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352220P | 2016-06-20 | 2016-06-20 | |
| US201662397575P | 2016-09-21 | 2016-09-21 | |
| PCT/US2017/038121 WO2017222977A1 (en) | 2016-06-20 | 2017-06-19 | Crystalline solid forms of a bet inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA124106C2 true UA124106C2 (uk) | 2021-07-21 |
Family
ID=59258384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201900524A UA124106C2 (uk) | 2016-06-20 | 2017-06-19 | Кристалічні тверді форми інгібітора bet |
| UAA202008134A UA125476C2 (uk) | 2016-06-20 | 2017-06-19 | Спосіб отримання 2,2,4-триметил-8-(6-метил-7-оксо-6,7-дигідро-1н-піроло[2,3-c]піридин-4-іл)-6-(метилсульфоніл)-2н-бензо[b][1,4]оксазин-3(4н)-ону і проміжних сполук |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202008134A UA125476C2 (uk) | 2016-06-20 | 2017-06-19 | Спосіб отримання 2,2,4-триметил-8-(6-метил-7-оксо-6,7-дигідро-1н-піроло[2,3-c]піридин-4-іл)-6-(метилсульфоніл)-2н-бензо[b][1,4]оксазин-3(4н)-ону і проміжних сполук |
Country Status (34)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970282B1 (en) | 2013-03-15 | 2019-08-21 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| MY207899A (en) | 2014-04-23 | 2025-03-27 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| DK3472157T3 (da) | 2016-06-20 | 2023-05-01 | Incyte Corp | Krystallinske faste former af en bet-inhibitor |
| TWI882964B (zh) * | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
| CA3176661A1 (en) * | 2020-04-24 | 2021-10-28 | Memorial Sloan-Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| DK4161528T3 (da) | 2020-06-03 | 2025-11-24 | Incyte Corp | Kombination af ruxolitinib med incb057643 til anvendelse ved behandling af myeloproliferative neoplasmer |
| CN112137961A (zh) * | 2020-09-30 | 2020-12-29 | 严鹏科 | 一种雷帕霉素组合物及其制备方法 |
| US20240139175A1 (en) * | 2020-12-23 | 2024-05-02 | Cascade Prodrug Inc. | Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (167)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59170313A (ja) | 1983-03-14 | 1984-09-26 | Kurimoto Iron Works Ltd | スクリ−ンゲ−ト |
| JPS6085739U (ja) | 1983-11-18 | 1985-06-13 | クラリオン株式会社 | テ−プレコ−ダにおけるピンチロ−ラ装置 |
| JPS6243003U (enExample) | 1985-09-05 | 1987-03-14 | ||
| JPH0314566A (ja) | 1989-06-09 | 1991-01-23 | Sankyo Co Ltd | ベンズイミダゾール誘導体 |
| US5244912A (en) | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
| FR2710915B1 (fr) | 1993-10-04 | 1995-11-24 | Synthelabo | Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique. |
| GB9410469D0 (en) | 1994-05-25 | 1994-07-13 | Erba Farmitalia | Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation |
| FR2731708B1 (fr) | 1995-03-13 | 1997-04-30 | Synthelabo | Derives de piperidine, leur procede de preparation et leur application en therapeutique |
| FR2747678B1 (fr) | 1996-04-22 | 1998-05-22 | Synthelabo | Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique |
| US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| AU5311401A (en) | 2000-04-21 | 2001-11-07 | Upjohn Co | Compounds for treating fibromyalgia and chronic fatigue syndrome |
| AU2002215608B2 (en) | 2000-06-28 | 2004-12-09 | Smithkline Beecham P.L.C. | Wet milling process |
| FR2816619B1 (fr) | 2000-11-15 | 2003-01-31 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| US6794382B2 (en) | 2000-08-08 | 2004-09-21 | Sanofi-Synthelabo | Benzimidazole derivatives, preparation and therapeutic use thereof |
| US6919334B2 (en) | 2002-09-12 | 2005-07-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine |
| NZ539952A (en) | 2002-11-22 | 2008-05-30 | Japan Tobacco Inc | Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X |
| EP1462103A1 (en) | 2003-03-25 | 2004-09-29 | Faust Pharmaceuticals | NO donors, combination products and uses as modulators of neurotransmitter release |
| EP1719761A4 (en) | 2004-02-23 | 2007-10-10 | Dainippon Sumitomo Pharma Co | NEW HETEROCYCLIC CONNECTION |
| WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| DE102005011058A1 (de) | 2005-03-10 | 2006-09-14 | Merck Patent Gmbh | Substituierte Tetrahydro-pyrrolo-chinolinderivate |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| WO2007018998A2 (en) | 2005-08-05 | 2007-02-15 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| US8975259B2 (en) | 2007-04-27 | 2015-03-10 | University Of Rochester | Compositions and methods for inhibiting G protein signaling |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| WO2009020559A2 (en) | 2007-08-03 | 2009-02-12 | The J. David Gladstone Institutes | Agents that inhibit p-tefb interactions and methods of use thereof |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| DE102008052618A1 (de) | 2008-10-21 | 2010-04-22 | Henkel Ag & Co. Kgaa | Tricyclische Aldehyde und C,H-acide Verbindungen |
| JP5730281B2 (ja) | 2009-03-27 | 2015-06-10 | 武田薬品工業株式会社 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 |
| TW201103941A (en) | 2009-06-10 | 2011-02-01 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
| TW201105681A (en) | 2009-06-10 | 2011-02-16 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
| WO2011024987A1 (ja) | 2009-08-31 | 2011-03-03 | 塩野義製薬株式会社 | 芳香族縮合へテロ環誘導体およびそれらを含有する医薬組成物 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CN102781943B (zh) | 2009-11-05 | 2016-10-05 | 葛兰素史密丝克莱恩有限责任公司 | 苯并二氮杂*溴结构域抑制剂 |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| US9360482B2 (en) | 2009-11-05 | 2016-06-07 | Glaxosmithkline Llc | Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4 |
| NZ599258A (en) | 2009-11-05 | 2014-05-30 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| MX2012012353A (es) | 2010-04-23 | 2013-02-07 | Kineta Inc | Compuestos anti-virales. |
| US9301962B2 (en) | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
| WO2011143651A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
| BR122014024883A2 (pt) | 2010-05-14 | 2019-08-20 | Dana-Farber Cancer Institute, Inc. | Compostos no tratamento de neoplasia |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| ES2526671T3 (es) | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| EP2673269A1 (en) | 2011-02-09 | 2013-12-18 | F.Hoffmann-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| CN103547152A (zh) | 2011-02-23 | 2014-01-29 | 西奈山伊坎医学院 | 溴结构域蛋白的抑制剂作为基因表达的调节剂 |
| RU2013143747A (ru) | 2011-03-21 | 2015-04-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения |
| GB201106799D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012178208A2 (en) | 2011-06-24 | 2012-12-27 | The Trustees Of The Stevens Institute Of Technology | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
| JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
| WO2013019710A1 (en) | 2011-07-29 | 2013-02-07 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hiv |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| PT2751083T (pt) | 2011-08-31 | 2018-03-05 | Otsuka Pharma Co Ltd | Composto de quinolona |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| ES2632443T3 (es) | 2011-09-22 | 2017-09-13 | Viiv Healthcare Uk Limited | Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH |
| WO2013044511A1 (zh) | 2011-09-30 | 2013-04-04 | 沈阳蓝桑医药生物技术研发有限公司 | 含有瑞利格内酯的药物组合物及其应用 |
| WO2013060636A1 (en) | 2011-10-25 | 2013-05-02 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2773354B1 (en) | 2011-11-01 | 2019-06-12 | Resverlogix Corp. | Oral immediate release formulations for substituted quinazolinones |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20150133434A1 (en) | 2012-03-28 | 2015-05-14 | The J. David Gladstone Institutes | Compositions and Methods for Reactivating Latent Immunodeficiency Virus |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281396A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| JP5989229B2 (ja) | 2012-04-20 | 2016-09-07 | アッヴィ・インコーポレイテッド | イソインドロン誘導体 |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
| JP6215315B2 (ja) | 2012-06-12 | 2017-10-18 | アッヴィ・インコーポレイテッド | ピリジノンおよびピリダジノン誘導体 |
| IN2014DN11269A (enExample) | 2012-06-25 | 2015-10-09 | Oncoethix Sa | |
| US9610332B2 (en) | 2012-07-18 | 2017-04-04 | Massachusetts Institute Of Technology | Compositions and methods for modulating BRD4 bioactivity |
| US9890147B2 (en) | 2012-08-16 | 2018-02-13 | Bayer Pharma Aktiengesellshaft | 2,3-benzodiazepines |
| RU2015102772A (ru) | 2012-08-16 | 2016-10-10 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Бензодиазелипы для мелкоклеточного рака легкого |
| WO2014048945A1 (de) | 2012-09-28 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 5-aryl-triazolo-azepine |
| US20140107107A1 (en) | 2012-09-28 | 2014-04-17 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| PL2917181T3 (pl) | 2012-11-09 | 2020-08-24 | Mmv Medicines For Malaria Venture | Pochodne heteroarylowe i ich zastosowania |
| US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
| EP2920183B1 (en) | 2012-11-14 | 2017-03-08 | Glaxosmithkline LLC | Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| CA2895404A1 (en) | 2012-12-20 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydropyridopyrazinones |
| WO2014095775A1 (de) | 2012-12-20 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydrochinoxalinone |
| CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| CN105189488B (zh) | 2013-02-27 | 2018-07-24 | 百时美施贵宝公司 | 用作溴区结构域抑制剂的咔唑化合物 |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| WO2014164771A1 (en) | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Bromodomain inhibitors |
| JP6401773B2 (ja) | 2013-03-11 | 2018-10-10 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法 |
| WO2014164780A1 (en) | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Fused tetracyclic bromodomain inhibitors |
| CN105164130A (zh) | 2013-03-12 | 2015-12-16 | 艾伯维公司 | 二氢-吡咯并吡啶酮布罗莫结构域抑制剂 |
| CA2903910C (en) | 2013-03-12 | 2023-08-15 | Steven D. FIDANZE | Triazadibenzo[cd,f]azulene derivatives and pharmaceutical compositions thereof useful as bromodomain inhibitors |
| JP2016512542A (ja) | 2013-03-12 | 2016-04-28 | アッヴィ・インコーポレイテッド | ピロールアミド阻害剤 |
| EP2970127B1 (en) | 2013-03-14 | 2018-10-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| JP6280573B2 (ja) | 2013-03-14 | 2018-02-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害薬としてのフロピリジン |
| KR20150135359A (ko) | 2013-03-14 | 2015-12-02 | 컨버진 엘엘씨 | 브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물 |
| RU2680100C9 (ru) | 2013-03-15 | 2019-04-18 | Плексксикон Инк. | Гетероциклические соединения и их применения |
| EP2970282B1 (en) | 2013-03-15 | 2019-08-21 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| WO2014152029A2 (en) | 2013-03-15 | 2014-09-25 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
| WO2014154762A1 (en) | 2013-03-27 | 2014-10-02 | Boehringer Ingelheim International Gmbh | Dihydroquinazolinone analogues as brd4 inhibitors |
| JP6370368B2 (ja) | 2013-03-27 | 2018-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｒｄ４阻害剤としてのインドリノン類似体 |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| WO2014170350A1 (en) | 2013-04-17 | 2014-10-23 | Albert Ludwigs Universität Freiburg | Compounds for use as bromodomain inhibitors |
| AU2014256750B2 (en) | 2013-04-26 | 2018-08-23 | Beigene, Ltd. | Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| CN105209467B (zh) | 2013-05-27 | 2018-06-08 | 诺华股份有限公司 | 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途 |
| WO2014191911A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
| JP2016520118A (ja) | 2013-05-28 | 2016-07-11 | ノバルティス アーゲー | Ｂｅｔ阻害剤としてのピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用 |
| JP2016521722A (ja) | 2013-06-17 | 2016-07-25 | バイエル ファーマ アクチエンゲゼルシャフト | 置換フェニル−２，３−ベンゾジアゼピン |
| ITMI20130991A1 (it) | 2013-06-17 | 2014-12-18 | Industrie De Nora Spa | Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse. |
| HRP20200854T1 (hr) | 2013-06-21 | 2020-08-21 | Zenith Epigenetics Ltd. | Novi biciklički inhibitori bromodomene |
| WO2015004534A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| RU2016102647A (ru) | 2013-06-28 | 2017-08-01 | Эббви Инк. | Ингибиторы бромодомена |
| AR096758A1 (es) * | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
| AR096837A1 (es) | 2013-07-08 | 2016-02-03 | Incyte Corp | Heterociclos tricíclicos como inhibidores de proteínas bet |
| CA2917177C (en) | 2013-07-16 | 2022-07-12 | Basf Se | Herbicidal azines |
| EP3024327B1 (en) | 2013-07-25 | 2019-09-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| KR101672096B1 (ko) | 2013-09-30 | 2016-11-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 발광 소자 |
| US9034900B2 (en) | 2013-10-18 | 2015-05-19 | Quanticel Pharmaceuticals, Inc. | Bromodomain inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| US20150148372A1 (en) | 2013-11-26 | 2015-05-28 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| EP3089970B1 (en) | 2013-12-09 | 2018-10-17 | AbbVie Inc. | Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| SG11201604916YA (en) | 2014-01-09 | 2016-07-28 | Orion Corp | Bicyclic heterocyclic derivatives as bromodomain inhibitors |
| EP3110818B1 (en) | 2014-02-28 | 2019-10-23 | The Regents of The University of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| CN106232595B (zh) | 2014-04-23 | 2020-01-14 | 巴斯夫欧洲公司 | 作为除草剂的二氨基三嗪化合物 |
| MY207899A (en) * | 2014-04-23 | 2025-03-27 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| AU2015250610B2 (en) | 2014-04-23 | 2019-02-07 | Takeda Pharmaceutical Company Limited | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease |
| EP3137086A4 (en) | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
| JP2017514909A (ja) | 2014-05-02 | 2017-06-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる急性骨髄性白血病及び／又は急性リンパ芽球性白血病の治療方法 |
| WO2015169953A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
| RU2016147946A (ru) | 2014-05-08 | 2018-06-08 | Онкоэтикс Гмбх | Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений |
| US10065951B2 (en) | 2014-05-30 | 2018-09-04 | Icahn School Of Medicine At Mount Sinai | Small molecule transcription modulators of bromodomains |
| JP6682522B2 (ja) | 2014-06-20 | 2020-04-15 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ２−（（４ｓ）−６−（４−クロロフェニル）−１−メチル−４ｈ−ベンゾ［ｃ］イソオキサゾロ［４，５−ｅ］アゼピン−４−イル）アセトアミドの結晶形態 |
| US9861077B2 (en) | 2014-07-11 | 2018-01-09 | Jaan Aked-Hurditch | Leash accessory |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| HUE050706T2 (hu) | 2014-10-24 | 2020-12-28 | Bristol Myers Squibb Co | Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként |
| MA40943A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016123709A1 (en) | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
| WO2016186453A1 (en) | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Quinoline derivatives as bromodomain inhibitors |
| WO2016194806A1 (ja) | 2015-05-29 | 2016-12-08 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する含窒素３環性誘導体 |
| CN105039258B (zh) | 2015-07-03 | 2018-04-17 | 北京大学 | 将非神经元细胞重编程为神经元样细胞的方法和组合物 |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CN105254635A (zh) | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
| US20170127985A1 (en) | 2015-11-11 | 2017-05-11 | Medtronic Minimed, Inc. | Sensor set |
| CN108602821B (zh) | 2015-12-14 | 2021-06-29 | 恒元生物医药科技(苏州)有限公司 | 1h-咪唑并[4,5-b]吡啶基bet溴结构域抑制剂 |
| WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| CN108770356A (zh) | 2016-02-05 | 2018-11-06 | 正大天晴药业集团股份有限公司 | 溴区结构域蛋白抑制剂的三环类化合物及其制备、药物组合物和用途 |
| DK3472157T3 (da) | 2016-06-20 | 2023-05-01 | Incyte Corp | Krystallinske faste former af en bet-inhibitor |
| CN108069958A (zh) | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
-
2017
- 2017-06-19 DK DK17734590.7T patent/DK3472157T3/da active
- 2017-06-19 JP JP2018566525A patent/JP7096170B2/ja active Active
- 2017-06-19 KR KR1020197001805A patent/KR102460046B1/ko active Active
- 2017-06-19 KR KR1020247006758A patent/KR102888132B1/ko active Active
- 2017-06-19 SG SG11201811416VA patent/SG11201811416VA/en unknown
- 2017-06-19 WO PCT/US2017/038121 patent/WO2017222977A1/en not_active Ceased
- 2017-06-19 SM SM20230155T patent/SMT202300155T1/it unknown
- 2017-06-19 EP EP23160938.9A patent/EP4234554A3/en active Pending
- 2017-06-19 SI SI201731358T patent/SI3472157T1/sl unknown
- 2017-06-19 CN CN202111443358.8A patent/CN114366748A/zh active Pending
- 2017-06-19 CN CN201780038099.6A patent/CN109715625B/zh active Active
- 2017-06-19 TW TW106120412A patent/TWI786050B/zh active
- 2017-06-19 PL PL17734590.7T patent/PL3472157T3/pl unknown
- 2017-06-19 TW TW113101597A patent/TWI854936B/zh active
- 2017-06-19 MY MYPI2018002677A patent/MY198892A/en unknown
- 2017-06-19 NZ NZ749956A patent/NZ749956A/en unknown
- 2017-06-19 MD MDE20190507T patent/MD3472157T2/ro unknown
- 2017-06-19 US US15/626,539 patent/US10189832B2/en active Active
- 2017-06-19 KR KR1020257037981A patent/KR20250163425A/ko active Pending
- 2017-06-19 FI FIEP17734590.7T patent/FI3472157T3/fi active
- 2017-06-19 HR HRP20230466TT patent/HRP20230466T1/hr unknown
- 2017-06-19 PT PT177345907T patent/PT3472157T/pt unknown
- 2017-06-19 IL IL263824A patent/IL263824B2/en unknown
- 2017-06-19 EP EP17734590.7A patent/EP3472157B1/en active Active
- 2017-06-19 CA CA3028689A patent/CA3028689A1/en active Pending
- 2017-06-19 PH PH1/2021/551887A patent/PH12021551887A1/en unknown
- 2017-06-19 PE PE2018003269A patent/PE20190623A1/es unknown
- 2017-06-19 LT LTEPPCT/US2017/038121T patent/LT3472157T/lt unknown
- 2017-06-19 SG SG10201912398PA patent/SG10201912398PA/en unknown
- 2017-06-19 MY MYPI2023005532A patent/MY209750A/en unknown
- 2017-06-19 PH PH1/2021/551886A patent/PH12021551886A1/en unknown
- 2017-06-19 CN CN202111446313.6A patent/CN114369091A/zh active Pending
- 2017-06-19 RS RS20230430A patent/RS64274B1/sr unknown
- 2017-06-19 CR CR20190027A patent/CR20190027A/es unknown
- 2017-06-19 CA CA3220957A patent/CA3220957A1/en active Pending
- 2017-06-19 AU AU2017281286A patent/AU2017281286B2/en active Active
- 2017-06-19 PE PE2023002468A patent/PE20240236A1/es unknown
- 2017-06-19 KR KR1020227036514A patent/KR102643344B1/ko active Active
- 2017-06-19 UA UAA201900524A patent/UA124106C2/uk unknown
- 2017-06-19 UA UAA202008134A patent/UA125476C2/uk unknown
- 2017-06-19 CA CA3220975A patent/CA3220975A1/en active Pending
- 2017-06-19 ES ES17734590T patent/ES2945063T3/es active Active
- 2017-06-19 HU HUE17734590A patent/HUE062234T2/hu unknown
- 2017-06-19 IL IL302528A patent/IL302528A/en unknown
- 2017-06-19 TW TW111147670A patent/TWI830533B/zh active
- 2017-06-19 MX MX2018016281A patent/MX389145B/es unknown
- 2017-06-19 CR CR20220651A patent/CR20220651A/es unknown
-
2018
- 2018-12-07 US US16/213,202 patent/US10626114B2/en active Active
- 2018-12-19 MX MX2023009524A patent/MX2023009524A/es unknown
- 2018-12-19 CL CL2018003702A patent/CL2018003702A1/es unknown
- 2018-12-19 MX MX2021009776A patent/MX2021009776A/es unknown
- 2018-12-20 PH PH12018502709A patent/PH12018502709A1/en unknown
- 2018-12-28 CO CONC2018/0014339A patent/CO2018014339A2/es unknown
-
2019
- 2019-01-10 EC ECSENADI20191982A patent/ECSP19001982A/es unknown
-
2020
- 2020-02-19 CL CL2020000407A patent/CL2020000407A1/es unknown
- 2020-02-19 CL CL2020000408A patent/CL2020000408A1/es unknown
- 2020-03-24 US US16/828,031 patent/US11091480B2/en active Active
- 2020-12-18 US US17/127,351 patent/US11377446B2/en active Active
-
2021
- 2021-08-09 AU AU2021215112A patent/AU2021215112B2/en active Active
- 2021-08-17 IL IL285686A patent/IL285686B/en unknown
-
2022
- 2022-03-29 JP JP2022053417A patent/JP7375082B2/ja active Active
- 2022-06-02 US US17/830,494 patent/US12030882B2/en active Active
- 2022-07-01 JP JP2022107131A patent/JP7588622B2/ja active Active
-
2023
- 2023-06-15 CY CY20231100282T patent/CY1126092T1/el unknown
- 2023-09-11 AU AU2023229471A patent/AU2023229471B2/en active Active
- 2023-10-25 JP JP2023183248A patent/JP7789735B2/ja active Active
-
2024
- 2024-05-28 US US18/675,780 patent/US12459943B2/en active Active
- 2024-06-03 JP JP2024089725A patent/JP7727794B2/ja active Active
-
2025
- 2025-07-31 JP JP2025128117A patent/JP2025176008A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA124106C2 (uk) | Кристалічні тверді форми інгібітора bet | |
| HK40099391A (en) | Crystalline solid forms of a bet inhibitor | |
| EA045891B1 (ru) | Кристаллические твердые формы ингибитора bet | |
| EA043645B1 (ru) | Кристаллические твердые формы ингибитора bet | |
| HK40006034A (en) | Crystalline solid forms of a bet inhibitor | |
| HK40006034B (en) | Crystalline solid forms of a bet inhibitor | |
| NZ787662A (en) | Crystalline solid forms of a bet inhibitor | |
| BR112018076486B1 (pt) | Formas sólidas cristalinas de um inibidor de bet, seus processo de preparação, composição farmacêutica e usos das mesmas | |
| BR122024012313A2 (pt) | Formas sólidas cristalinas de um inibidor de bet, composição farmacêutica e usos das mesmas |